| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yuwei Wang | |
| David W Grainger | |||
| P2860 | cites work | DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells | Q24290803 |
| Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2 | Q24291299 | ||
| Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP | Q24295390 | ||
| Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55 | Q24297487 | ||
| Stimulation by toll-like receptors inhibits osteoclast differentiation | Q24301850 | ||
| The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor | Q24302449 | ||
| Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP | Q24302943 | ||
| Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia | Q24309601 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction | Q24318608 | ||
| IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation | Q24321727 | ||
| A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB | Q24321775 | ||
| RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytes | Q24533459 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro | Q24629421 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Role of transmembrane 4 superfamily (TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance | Q24683519 | ||
| Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption | Q24797422 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 | Q27860854 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| Structure and properties of the vacuolar (H+)-ATPases | Q27937111 | ||
| Focal adhesion kinase regulation of N-WASP subcellular localization and function | Q28118737 | ||
| Regulators of G protein signaling exhibit distinct patterns of gene expression and target G protein specificity in human lymphocytes | Q28138524 | ||
| Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis | Q28140437 | ||
| Creatine and creatinine metabolism | Q28140735 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man | Q28201425 | ||
| Proton-sensing G-protein-coupled receptors | Q28205003 | ||
| Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation | Q28206691 | ||
| The myosin power stroke | Q28216645 | ||
| Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase | Q28278061 | ||
| A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis | Q28297820 | ||
| RANKL-induced DC-STAMP is essential for osteoclastogenesis | Q28504881 | ||
| Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects | Q28505493 | ||
| Diversity of mouse proton-translocating ATPase: presence of multiple isoforms of the C, d and G subunits | Q28505548 | ||
| The gamete fusion process is defective in eggs of Cd9-deficient mice | Q28505612 | ||
| DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells | Q28506839 | ||
| Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation | Q28511207 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice | Q44964483 | ||
| Injectable PLGA microsphere/calcium phosphate cements: physical properties and degradation characteristics | Q45103177 | ||
| Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs | Q45147309 | ||
| Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy | Q45864343 | ||
| Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene | Q45867824 | ||
| Clinical trials in the gene therapy of arthritis | Q45871812 | ||
| Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice | Q45874107 | ||
| Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo | Q45879134 | ||
| Gene therapy for osteoporosis: evaluation in a murine ovariectomy model | Q45882776 | ||
| Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse | Q45885673 | ||
| Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. | Q45887309 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. | Q45931469 | ||
| Biomechanical evaluation of kyphoplasty with calcium sulfate cement in a cadaveric osteoporotic vertebral compression fracture model. | Q45946615 | ||
| Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. | Q46041414 | ||
| Activation of Src kinase by protein-tyrosine phosphatase-PEST in osteoclasts: comparative analysis of the effects of bisphosphonate and protein-tyrosine phosphatase inhibitor on Src activation in vitro | Q46058982 | ||
| Reports of esophageal cancer with oral bisphosphonate use. | Q46178055 | ||
| Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. | Q46188888 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption | Q46413291 | ||
| Mutation of amino acid residues in the putative transmembrane segments of the cardiac sarcolemmal Na+-Ca2+ exchanger | Q46450185 | ||
| Purification of the cardiac Na+-Ca2+ exchange protein | Q46689861 | ||
| Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis | Q46961300 | ||
| Injectable bioactive calcium-magnesium phosphate cement for bone regeneration | Q47218915 | ||
| RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. | Q47256563 | ||
| Predicting gene expression from sequence | Q47765918 | ||
| Actin-related protein 2/3 complex is required for actin ring formation | Q47893344 | ||
| The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression | Q47955115 | ||
| Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates | Q48087195 | ||
| Subunit interactions in the clathrin-coated vesicle vacuolar (H(+))-ATPase complex | Q48101144 | ||
| Calcium phosphate cements: competitive drug carriers for the musculoskeletal system? | Q51308821 | ||
| Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts | Q34144752 | ||
| Gene therapies for osteoarthritis | Q34288778 | ||
| Role of Toll-like receptors in inflammatory response in macrophages | Q34303788 | ||
| Involvement of the orphan nuclear estrogen receptor-related receptor α in osteoclast adhesion and transmigration | Q34343307 | ||
| Technological issues for the development of more efficient calcium phosphate bone cements: a critical assessment. | Q34427419 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts | Q34561156 | ||
| RNAi therapeutics: principles, prospects and challenges | Q34621268 | ||
| NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts | Q34711561 | ||
| Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 | Q34764750 | ||
| Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. | Q34774678 | ||
| Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro | Q34793691 | ||
| Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures | Q34890347 | ||
| The Na+/Ca2+ exchange molecule: an overview. | Q35034485 | ||
| The p53-Mdm2 module and the ubiquitin system. | Q35036580 | ||
| Functional osteoclast attachment requires inositol-1,4,5-trisphosphate receptor-associated cGMP-dependent kinase substrate | Q35043582 | ||
| Design strategies to improve soluble macromolecular delivery constructs | Q35082134 | ||
| Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts | Q35126799 | ||
| Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis. | Q35185600 | ||
| Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice | Q35194925 | ||
| Erythrocyte K-Cl cotransport: properties and regulation | Q35534126 | ||
| Fracture Fixation | Q35582762 | ||
| Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts | Q35605683 | ||
| Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice | Q35607627 | ||
| Massachusetts General Hospital/Harvard Medical School MD oral and maxillofacial surgery program: a 30-year review | Q35618145 | ||
| Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases | Q35762495 | ||
| Regulation of WASP: PIP2 Pipped by Toca-1? | Q35839643 | ||
| Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis | Q35860271 | ||
| Interaction between osteoblast and osteoclast: impact in bone disease | Q35891193 | ||
| Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. | Q35916038 | ||
| Organization of osteoclast microfilaments during the attachment to bone surface in vitro. | Q35938974 | ||
| Evolutionary origins of eukaryotic sodium/proton exchangers | Q36005608 | ||
| Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics | Q36117588 | ||
| Bone-targeting macromolecular therapeutics. | Q36117609 | ||
| Gene therapy for the treatment of musculoskeletal diseases. | Q36236529 | ||
| Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength | Q36316394 | ||
| Osteoclast precursors, RANKL/RANK, and immunology | Q36324916 | ||
| Two pathways through Cdc42 couple the N-formyl receptor to actin nucleation in permeabilized human neutrophils | Q36328789 | ||
| Short interfering RNA (siRNA): tool or therapeutic? | Q36334989 | ||
| Drug/device combinations for local drug therapies and infection prophylaxis | Q36335731 | ||
| I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss | Q36402985 | ||
| Podosome and sealing zone: specificity of the osteoclast model | Q36424995 | ||
| NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis | Q36490904 | ||
| RNAi therapeutics: a potential new class of pharmaceutical drugs | Q36654918 | ||
| A histone methyltransferase is required for maximal response to female sex hormones | Q36701489 | ||
| Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis | Q36732279 | ||
| Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 | ||
| Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. | Q36792039 | ||
| Dissociation between bone resorption and bone formation in osteopenic transgenic mice | Q36800774 | ||
| Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. | Q36805693 | ||
| The role of NFAT in osteoclast formation | Q37033696 | ||
| Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts | Q28568502 | ||
| ADAM8: a novel osteoclast stimulating factor | Q28588620 | ||
| Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway | Q28592087 | ||
| Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha | Q28593804 | ||
| The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly | Q28609843 | ||
| The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation | Q29400446 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells | Q29547714 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells | Q30156881 | ||
| Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT | Q30157087 | ||
| Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation | Q30175955 | ||
| Signalling by the p60c-src family of protein-tyrosine kinases | Q30193393 | ||
| Myosin X regulates sealing zone patterning in osteoclasts through linkage of podosomes and microtubules | Q30493830 | ||
| Analysis of the signaling pathways regulating Src-dependent remodeling of the actin cytoskeleton | Q30497716 | ||
| Selective drug delivery system to bone: small peptide (Asp)6 conjugation | Q30869292 | ||
| Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. | Q30944070 | ||
| Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice | Q31957843 | ||
| Oligonucleotide‐Based Knockdown Technologies: Antisense Versus RNA Interference | Q33193599 | ||
| Combination of scaffold and adenovirus vectors expressing bone morphogenetic protein-7 for alveolar bone regeneration at dental implant defects | Q33292518 | ||
| RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis | Q33370006 | ||
| Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage | Q33509923 | ||
| The Arp2/3 complex: a multifunctional actin organizer | Q33536484 | ||
| The structural era of endocytosis | Q33683033 | ||
| Gentamicin release from commercially-available gentamicin-loaded PMMA bone cements in a prosthesis-related interfacial gap model and their antibacterial efficacy | Q33743608 | ||
| Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. | Q33752819 | ||
| Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts | Q33850016 | ||
| siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption | Q33912421 | ||
| Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. | Q33913012 | ||
| Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. | Q33913718 | ||
| Myosin-X, a novel myosin with pleckstrin homology domains, associates with regions of dynamic actin. | Q33917620 | ||
| Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts | Q33939357 | ||
| Severely suppressed bone turnover: a potential complication of alendronate therapy | Q33983792 | ||
| Therapeutic approaches to bone diseases | Q34021178 | ||
| Targeted gene silencing using RGD-labeled chitosan nanoparticles | Q34031859 | ||
| Phosphatidylinositol 4,5-bisphosphate induces actin-based movement of raft-enriched vesicles through WASP-Arp2/3. | Q42803796 | ||
| Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix | Q42990448 | ||
| beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells | Q43298697 | ||
| Setting characteristics and mechanical behaviour of a calcium phosphate bone cement containing tetracycline. | Q43580609 | ||
| Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling | Q43648531 | ||
| New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand | Q43667822 | ||
| Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study | Q43791673 | ||
| Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic | Q43968160 | ||
| Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. | Q43987361 | ||
| The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength | Q44046705 | ||
| ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1 | Q44135907 | ||
| Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes | Q44362843 | ||
| Atypical fractures as a potential complication of long-term bisphosphonate therapy | Q44372111 | ||
| Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. | Q44585934 | ||
| Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study | Q44709291 | ||
| Regulation of the type 1 inositol 1,4,5-trisphosphate receptor by phosphorylation at tyrosine 353. | Q44755165 | ||
| TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function | Q44912776 | ||
| Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis | Q44920044 | ||
| Inhibition of the osteoclast V-ATPase by small interfering RNAs | Q81098185 | ||
| Drugs for prevention and treatment of postmenopausal osteoporosis | Q81246923 | ||
| Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors | Q81489492 | ||
| Long-term safety of bisphosphonates | Q81502820 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| Localized delivery of antisense oligonucleotides by cationic hydrogel suppresses TNF-α expression and endotoxin-induced osteolysis | Q82794580 | ||
| Localized, targeted, and sustained siRNA delivery | Q83460693 | ||
| RNA interference-based gene therapy for successful treatment of rheumatoid arthritis | Q83728894 | ||
| Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis | Q83856360 | ||
| High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. | Q37065282 | ||
| The design of vectors for RNAi delivery system | Q37185062 | ||
| Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA | Q37219628 | ||
| Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation | Q37286240 | ||
| Osteoporosis: how long should we treat? | Q37312945 | ||
| Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo | Q37346696 | ||
| A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo | Q37366963 | ||
| Bone health - An investment | Q37388070 | ||
| Lipidic systems for in vivo siRNA delivery | Q37598096 | ||
| Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference | Q37704644 | ||
| p53-targeted cancer pharmacotherapy: move towards small molecule compounds | Q37865050 | ||
| Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase Alpha-mediated mechanism | Q38287550 | ||
| Microarray profile of gene expression during osteoclast differentiation in modelled microgravity. | Q38341566 | ||
| Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator | Q38363724 | ||
| Skeletal repair by in situ formation of the mineral phase of bone | Q38505425 | ||
| Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry--a 3-year follow-up study | Q38524759 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis | Q39365959 | ||
| Retinoblastoma protein-interacting zinc finger 1 (RIZ1) participates in RANKL-induced osteoclast formation via regulation of NFATc1 expression | Q39711113 | ||
| Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | Q39714931 | ||
| Synthesis and physical and physiological properties of 4'-thioRNA: application to post-modification of RNA aptamer toward NF-kappaB | Q39752190 | ||
| The role of Mac-1 (CD11b/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-kappaB ligand | Q39942676 | ||
| Silencing of YY1 downregulates RIZ1 promoter in human osteosarcoma. | Q39980827 | ||
| AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells | Q40075875 | ||
| RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway | Q40118270 | ||
| Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis | Q40130750 | ||
| Targeted deletion of the osteoclast protein-tyrosine phosphatase (PTP-oc) promoter prevents RANKL-mediated osteoclastic differentiation of RAW264.7 cells. | Q40133607 | ||
| Morphological features of osteoclasts derived from a co-culture system. | Q40231635 | ||
| Expression of and role for ovarian cancer G-protein-coupled receptor 1 (OGR1) during osteoclastogenesis. | Q40264908 | ||
| RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis | Q40271536 | ||
| Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis | Q40437124 | ||
| TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. | Q40542323 | ||
| N-linked sialyated sugar receptors support haematopoietic cell-osteoblast adhesions | Q40585793 | ||
| The signaling adapter protein DAP12 regulates multinucleation during osteoclast development | Q40589041 | ||
| The role of LFA-1 in osteoclast development induced by co-cultures of mouse bone marrow cells and MC3T3-G2/PA6 cells | Q40718919 | ||
| Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation | Q40832683 | ||
| Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling | Q40890957 | ||
| RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. | Q41107411 | ||
| Basolateral KCl co-transport in a NaCl-absorbing epithelium | Q41588404 | ||
| Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors | Q41607334 | ||
| The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats | Q41682619 | ||
| Heterotrimeric G protein signaling: roles in immune function and fine-tuning by RGS proteins | Q41700415 | ||
| Gaucher's disease: studies of gene transfer to haematopoietic cells | Q41719206 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts | Q42043704 | ||
| Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation | Q42426515 | ||
| Intracellular ClC-3 chloride channels promote bone resorption in vitro through organelle acidification in mouse osteoclasts | Q42524180 | ||
| Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption | Q42527337 | ||
| Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. | Q51947476 | ||
| Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action. | Q51985828 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| A novel skeletal drug delivery system using self-setting calcium phosphate cement. 9: Effects of the mixing solution volume on anticancer drug release from homogeneous drug-loaded cement. | Q52340881 | ||
| A novel skeletal drug delivery system using a self-setting calcium phosphate cement. 5. Drug release behavior from a heterogeneous drug-loaded cement containing an anticancer drug. | Q52366882 | ||
| The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. | Q52509359 | ||
| Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. | Q52537176 | ||
| A microtubule-binding myosin required for nuclear anchoring and spindle assembly. | Q52560093 | ||
| Coordination of microtubules and the actin cytoskeleton is important in osteoclast function, but calcitonin disrupts sealing zones without affecting microtubule networks. | Q52571447 | ||
| MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. | Q52580047 | ||
| Application of small interfering RNA for inhibition of lipopolysaccharide-induced osteoclast formation and cytokine stimulation. | Q53481036 | ||
| Chemical modification of siRNAs to improve serum stability without loss of efficacy. | Q53600125 | ||
| Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. | Q53672361 | ||
| Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA. | Q54644666 | ||
| The RNAi revolution. | Q55038521 | ||
| Trafficking of Matrix Collagens Through Bone-Resorbing Osteoclasts | Q56341625 | ||
| Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 | ||
| Regulation of Actin Ring Formation by Rho GTPases in Osteoclasts | Q57372361 | ||
| JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms | Q58326878 | ||
| Genetic control of skeletal development | Q58326890 | ||
| TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors | Q59225103 | ||
| WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption | Q61053891 | ||
| Bisphosphonates | Q61786757 | ||
| Phosphorylation of a Wiscott-Aldrich syndrome protein-associated signal complex is critical in osteoclast bone resorption | Q64377259 | ||
| Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures | Q68274092 | ||
| Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro | Q69244135 | ||
| Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate | Q70845000 | ||
| Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis | Q71503443 | ||
| Direct stimulation of bone resorption by epidermal growth factor | Q72075897 | ||
| Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins | Q72865482 | ||
| Particle opsonization and lung macrophage cytokine response. In vitro and in vivo analysis | Q72901016 | ||
| Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1) | Q73339269 | ||
| Transforming growth factor-beta1 incorporated during setting in calcium phosphate cement stimulates bone cell differentiation in vitro | Q73379018 | ||
| Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis | Q73794664 | ||
| Effects of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement | Q74148811 | ||
| Targeting systemically administered proteins to bone by bisphosphonate conjugation | Q74251618 | ||
| In vitro elution of gentamicin, amikacin, and ceftiofur from polymethylmethacrylate and hydroxyapatite cement | Q74351252 | ||
| Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women | Q74586981 | ||
| Involvement of lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 in osteoclastogenesis: a possible role in direct interaction between osteoclast precursors | Q77180427 | ||
| RNA interference targeting Fas protects mice from fulminant hepatitis | Q78961966 | ||
| Osteoclastic differentiation and function regulated by old and new pathways | Q79370827 | ||
| Three Na+/Ca2+ exchanger (NCX) variants are expressed in mouse osteoclasts and mediate calcium transport during bone resorption | Q79818794 | ||
| Expression of mouse osteoclast K-Cl Co-transporter-1 and its role during bone resorption | Q79822562 | ||
| A transmembrane osteoclastic protein-tyrosine phosphatase regulates osteoclast activity in part by promoting osteoclast survival through c-Src-dependent activation of NFkappaB and JNK2 | Q80074246 | ||
| The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis | Q80337310 | ||
| Percutaneous injection of recombinant human bone morphogenetic protein-2 in a calcium phosphate paste accelerates healing of a canine tibial osteotomy | Q80337437 | ||
| The in vitro antibiotic release from anti-washout apatite cement using chitosan | Q80528155 | ||
| Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models | Q80928315 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1341-1357 | |
| P577 | publication date | 2011-09-10 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | RNA therapeutics targeting osteoclast-mediated excessive bone resorption | |
| P478 | volume | 64 |
| Q42659386 | A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy |
| Q38570326 | Appropriate models for novel osteoporosis drug discovery and future perspectives |
| Q33901933 | Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. |
| Q36137494 | Biomaterial strategies for engineering implants for enhanced osseointegration and bone repair |
| Q55515922 | Bisphosphonate conjugation for bone specific drug targeting. |
| Q38151734 | Developing siRNA therapies to address osteoporosis |
| Q36928118 | Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. |
| Q57039753 | Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy |
| Q38076055 | RNA interference--a silent but an efficient therapeutic tool |
| Q42052780 | Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials |
| Q39020213 | Small non-coding RNAs-based bone regulation and targeting therapeutic strategies. |
Search more.